Literature DB >> 18159385

Mupirocin - Are we in danger of losing it?

John M Conly1, B Lynn Johnston.   

Abstract

Entities:  

Year:  2002        PMID： 18159385      PMCID： PMC2094870          DOI： 10.1155/2002/692581

Source DB:  PubMed          Journal:  Can J Infect Dis        ISSN： 1180-2332


× No keyword cloud information.
  22 in total

1.  High-level mupirocin resistance among Spanish methicillin-resistant Staphylococcus aureus.

Authors:  T Alarcón; J C Sanz; F Blanco; D Domingo; M López-Brea
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-12       Impact factor: 3.267

Review 2.  Mupirocin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A Ward; D M Campoli-Richards
Journal:  Drugs       Date:  1986-11       Impact factor: 9.546

3.  Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis.

Authors:  Miguel Pérez-Fontán; Miguel Rosales; Ana Rodríguez-Carmona; Teresa García Falcón; Francisco Valdés
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

4.  Mupirocin-resistant methicillin-resistant Staphylococcus aureus in Western Australia.

Authors:  T V Riley; C F Carson; R A Bowman; L Mulgrave; C L Golledge; J W Pearman; W B Grubb
Journal:  Med J Aust       Date:  1994-09-19       Impact factor: 7.738

5.  Emergence of mupirocin resistance in multiresistant Staphylococcus aureus clinical isolates belonging to Brazilian epidemic clone III::B:A.

Authors:  R L B Ramos; L A Teixeira; L R Ormonde; P L A Siqueira; M S Santos; D Marangoni; A M S Figueiredo
Journal:  J Med Microbiol       Date:  1999-03       Impact factor: 2.472

6.  Heterogeneous location of the mupA high-level mupirocin resistance gene in Staphylococcus aureus.

Authors:  N Woodford; A P Watson; S Patel; M Jevon; D J Waghorn; B D Cookson
Journal:  J Med Microbiol       Date:  1998-09       Impact factor: 2.472

7.  The epidemiology of mupirocin resistance among methicillin-resistant Staphylococcus aureus at a Veterans' Affairs hospital.

Authors:  J E Vasquez; E S Walker; B W Franzus; B K Overbay; D R Reagan; F A Sarubbi
Journal:  Infect Control Hosp Epidemiol       Date:  2000-07       Impact factor: 3.254

8.  Emergence of high-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from Brazilian university hospitals.

Authors:  K R Netto dos Santos; L de Souza Fonseca; P P Gontijo Filho
Journal:  Infect Control Hosp Epidemiol       Date:  1996-12       Impact factor: 3.254

9.  Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use.

Authors:  R Sutherland; R J Boon; K E Griffin; P J Masters; B Slocombe; A R White
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

10.  The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals.

Authors:  F J Schmitz; E Lindenlauf; B Hofmann; A C Fluit; J Verhoef; H P Heinz; M E Jones
Journal:  J Antimicrob Chemother       Date:  1998-10       Impact factor: 5.790
View more
  11 in total

Review 1.  Prevention of Recurrent Staphylococcal Skin Infections.

Authors:  C Buddy Creech; Duha N Al-Zubeidi; Stephanie A Fritz
Journal:  Infect Dis Clin North Am       Date:  2015-09       Impact factor: 5.982

2.  Synthesis and evaluation of topical hydrogel membranes; a novel approach to treat skin disorders.

Authors:  Sarfaraz Ahmad; Muhammad Usman Minhas; Mahmood Ahmad; Muhammad Sohail; Qandeel Khalid; Orva Abdullah
Journal:  J Mater Sci Mater Med       Date:  2018-12-11       Impact factor: 3.896

3.  Enzymatic glycosylation of the topical antibiotic mupirocin.

Authors:  Prakash Parajuli; Ramesh Prasad Pandey; Anaya Raj Pokhrel; Gopal Prasad Ghimire; Jae Kyung Sohng
Journal:  Glycoconj J       Date:  2014-07-30       Impact factor: 2.916

4.  Activity of retapamulin against Streptococcus pyogenes and Staphylococcus aureus evaluated by agar dilution, microdilution, E-test, and disk diffusion methodologies.

Authors:  Glenn A Pankuch; Gengrong Lin; Dianne B Hoellman; Caryn E Good; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

5.  Mupirocin and chlorhexidine resistance in Staphylococcus aureus in patients with community-onset skin and soft tissue infections.

Authors:  Stephanie A Fritz; Patrick G Hogan; Bernard C Camins; Ali J Ainsworth; Carol Patrick; Madeline S Martin; Melissa J Krauss; Marcela Rodriguez; Carey-Ann D Burnham
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

6.  Development of microsponges for topical delivery of mupirocin.

Authors:  Netal Amrutiya; Amrita Bajaj; Madhu Madan
Journal:  AAPS PharmSciTech       Date:  2009-04-21       Impact factor: 3.246

7.  Modeling the invasion of community-acquired methicillin-resistant Staphylococcus aureus into hospitals.

Authors:  Erica M C D'Agata; Glenn F Webb; Mary Ann Horn; Robert C Moellering; Shigui Ruan
Journal:  Clin Infect Dis       Date:  2009-02-01       Impact factor: 9.079

8.  Prevalence of qacA/B Genes and Mupirocin Resistance Among Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates in the Setting of Chlorhexidine Bathing Without Mupirocin.

Authors:  David K Warren; Martin Prager; Satish Munigala; Meghan A Wallace; Colleen R Kennedy; Kerry M Bommarito; John E Mazuski; Carey-Ann D Burnham
Journal:  Infect Control Hosp Epidemiol       Date:  2016-02-02       Impact factor: 3.254

9.  The prevalence and molecular mechanisms of mupirocin resistance in Staphylococcus aureus isolates from a Hospital in Cape Town, South Africa.

Authors:  Shima M Abdulgader; Tshepiso Lentswe; Andrew Whitelaw; Mae Newton-Foot
Journal:  Antimicrob Resist Infect Control       Date:  2020-03-14       Impact factor: 4.887

10.  Unusual source of recurrent Corynebacterium bacteraemia in an immunocompromised patient.

Authors:  Abdul Rahim Ali Bakhsh; Keir Edward Lewis
Journal:  BMJ Case Rep       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.